Abstract
Alemtuzumab (Lemtrada) is a humanized monoclonal antibody targeting the surface molecule CD 52 on immune cells. The bond between alemtuzumab and lymphocyte leads to cytolysis resulting to development of new lymphocyte generation potencially without autoaggressive signes of original population.
Nowadays, alemtuzumab is in Czech Republic (CR) approved for treatment of highly active relaps-remitting multiple sclerosis (RR MS). In this paper we describe 2 cases of patients on alemtuzumab treatment in our department.
We demonstrate both high efficacy confirmed in clinical trials together with potential risk of side effects following from mechanism of action.